Pharmacological Management of Obesity
Treatment
( 2 , L )
Drugs That Cause Weight Gain and Some Alternatives
In women with a BMI >27 kg/m2 with comorbidities or >30 kg/m2 seeking contraception, ES suggests oral contraceptives over injectable medications due to weight gain with injectables, provided that women are well-informed about the risks and benefits (i.e., oral contraceptives are not contraindicated).
( 2 , VL )Off-Label Use of Drugs Approved for Other Indications for Chronic Obesity Management
Recommendation Grading
Overview
Title
Pharmacological Management of Obesity
Authoring Organization
Endocrine Society
Endorsing Organization
The Obesity Society
Publication Month/Year
January 2, 2015
Last Updated Month/Year
November 5, 2024
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Document Objectives
To formulate clinical practice guidelines for the pharmacological management of obesity.
Target Patient Population
Patients who have been unsuccessful with diet and exercise alone
Inclusion Criteria
Male, Female, Adolescent, Adult, Child, Older adult
Health Care Settings
Ambulatory
Intended Users
Diabetes educator, dietician nutritionist, nurse, nurse practitioner, physician, physician assistant
Scope
Counseling, Treatment, Management
Diseases/Conditions (MeSH)
D009765 - Obesity, D019440 - Anti-Obesity Agents, D000073319 - Obesity Management
Keywords
obesity, overweight
Source Citation
Caroline M. Apovian, Louis J. Aronne, Daniel H. Bessesen, Marie E. McDonnell, M. Hassan Murad, Uberto Pagotto, Donna H. Ryan, Christopher D. Still, Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 100, Issue 2, 1 February 2015, Pages 342–362, https://doi.org/10.1210/jc.2014-3415